Combined immunoglobulin and azathioprine in multiple sclerosis.

dc.contributor.author	H Kalanie
dc.contributor.author	S S Tabatabai
dc.date.accessioned	2017-10-24T12:17:58Z
dc.date.available	2017-10-24T12:17:58Z
dc.identifier.citation	rft.volume=39&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.spage=178&rft.issue=3&rft.epage=81&ctx_ver=Z39.88-2004&rft.jtitle=European+neurology&rft.date=1998
dc.identifier.issn	0014-3022
dc.identifier.uri	http://dsp.sbmu.ac.ir/xmlui/handle/123456789/80682
dc.description.abstract	In an attempt to prevent exacerbations of multiple sclerosis, immunoglobulin therapy was combined with azathioprine (AZA). Intravenous immunoglobulin (i.v.IG) 2 g/kg was given in divided doses over 3 consecutive days followed by monthly booster doses (0.2 g/kg) for 3 years to 38 patients with relapsing-remitting multiple sclerosis (MS). In the 34 patients who completed the trial, the relapse rate decreased (from 1.7 relapses per year to 0 during the 3-year trial period). The Kurtzke Expanded Disability Status Scale decreased from 3.4 +/- 0.72 to 3.0 +/- 0.70. The results suggest that combined i.v.IG and AZA suppress the ongoing pathologic process in relapsing-remitting MS.
dc.source	European neurology
dc.title	Combined immunoglobulin and azathioprine in multiple sclerosis.

Files in this item

Files	Size	Format	View
There are no files associated with this item.